AMRN - Earnings announcements

Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026). "Our results for Q1 2026 reflected the early yet measurable progress generated by

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 877-545-0523 International dial in: 973-528-0016 Access Code: 459510  V

-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months --  -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market -- -- Cash Position Sufficient to Fund Company's Future Growth Path -- DUBLIN and BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial and operational results for the second quarter of 2025. "The strategic actions taken in the second quarter – our partnership with Recordati to a

DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2025 financial results in the pre-market hours on July 30th. Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.com Dial in within the Unite

-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA® (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partn

-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062Intern

-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise -- -- Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the fourth quarter of 2024 and

DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's fourth quarter 2024 financial results in the pre-market hours on March 12th.   Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States:

 -- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches ---- Positive European Momentum Continues with Progress from Pricing & Reimbursement Efforts and Incremental Revenue Growth Driven Primarily by Spain and the UK ---- Company to Host Virtual Analyst & Investor Day November 14 ---- Company Remains Committed to Maintaining Public Listing – DUBLIN and BRIDGEWATER, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the third quarter ended

-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results – October 30 – The Company will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, immediately following the close of market trading followed by a conference call with Amarin's senior management team at 5:00 pm ET. Conference Call and Webcast Information: Access to the live call:Go to the investor rela

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. Commenting on the Company, Aaron Berg, Amarin's President and CEO, said, "As I begin in my new role as CEO of Amarin, my focus is clear: drive value by focusing on

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engagement with the company's shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions

-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today provided an update on the Company'

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2024 financial results in the pre-market hours. To enhance engagement with the company's shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow retail and institutional shareholders to submit an

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million -- -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million ---- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 ---- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company's fourth quarter and full year 2023 financial results in the pre-market hours.   To enhance engagement with the company's shareholder base and facilitate connections with its investors, Amarin is p

-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million -- -- Company Continues to Deliver Significant U.S. Profit Through Extended Lifecycle and Market Leadership of Branded VASCEPA® -- -- Early Launch Progress in European Countries Driven by New Leadership -- -- Company to Host Conference Call Today at 8:00 a.m. ET -- DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended Sept

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss the Company's third quarter 2023 financial results on Wednesday, November 1st, 2023 at 8:00 a.m. ET. To enhance engagement with the company's shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. Starting on October 19th at

-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. -- -- Company Expects Restructuring to Drive Annual Cost Savings of Approximately $40 Million -- -- Announces Preliminary Earnings Results for Second Quarter 2023 -- -- Company to Host Conference Call Today at 5:00 p.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it has initiated an organizational restructuring program to right-size and strengthen the Company to enhance shareholder value. Over the last seve

-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy Progressing with CSL Seqirus Partnership for Australia & New Zealand -- -- Leadership Team and New Board of Directors Focused on Shareholder Value Creation -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2023 a

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin's senior management team to discuss the Company's first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2023 financial results in the pre-market hours. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States:

-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target -- -- European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and Strong Position for 2023 -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2022 and provided an update on the Company's operations. "2022 was a year of significant progress for the new Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's fourth quarter and year end 2022 financial results on Wednesday, March 1st , 2023 at 8:00 a.m. ET. The conference call with management will follow the release of the Company's fourth quarter 2022 financial results in the pre-market hours. Conference Call and Webcast Information:Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062International dial in

-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – -- Obtained Positive Scientific Assessment for Reimbursement in Italy and the Netherlands & Achieved Positive National Reimbursement in Finland -- --Ongoing Market Access Negotiations for VAZKEPA Underway Across Multiple Major European Markets Including Final Price Negotiations in Spain -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's third quarter 2022 financial results on Thursday, October 27th, 2022 at 8:00 a.m. ET. The conference call with management will follow the release of the Company's third quarter 2022 financial results in the pre-market hours. Conference Call and Webcast Information:Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062International dial in: 973-528-0011Acce

Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK's NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* Plans On Track for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to Host Conference Call Today at 8:00 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended J

DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2022 financial results in the pre-market hours. Conference Call and Webcast Information:Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062International dial in: 973-528-0011Access

 Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to Host Conference Call Today at 8:00 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2022 and provided an update on company operations. "In the first quarter of 2022,

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's first quarter 2022 financial results on Wednesday, May 4, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day. Conference Call and Webcast Information:Access to live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062International dial in: 973-528-0011Access Code: 930259 Access to replay:Dial i

Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several Additional Countries in 2022 Company to Host Conference Call Today at 8:00 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2021 and provided an update on company operations. "2021 was a year of significant progress, during which we laid the fo

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day. Conference Call and Webcast Information: Access to live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in with in the United States: 888-506-0062International dial in: 973-528-0011Access Code 424818 Access to re

Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries in 2022 Company to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the third quarter and nine months ended September 30, 2021 and provided an update on Company operations. Recent Key Amarin Highlights: Topline Financial Results: Total net revenue for the three and nine months ende

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin's senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day. Conference Call and Webcast Information: Amarin will host a conference call November 3, 2021, at 7:30 a.m. ET to discuss this information. The conference call can be heard live on the investor relations section of the Company's website at www.amarincorp.

Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately €200 per Month New CEO, Karim Mikhail, to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the second quarter and six months ended June 30, 2021 and provided an update on company operations. Recent Key Amarin Highlights: Second Quarter Revenue: Net total revenue in the second quarter of 2021 was $154.5 million, an increase of 14% when compared with $135.3 million in total net r

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate. The lawsuit was filed in the United States District Court in Delaware. A copy of the complaint is available in the FAQ section of Amarin’s investor relations website. The Amarin complaint alleges that Hikma has induced the infringement of U.S. Patent Nos. 9,700,537 (Composition for preventing the occurrence of cardiovascular event in multiple risk patient), 8,642,077 (Stable pharmaceutical composition and methods of